Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Marketing Status Prescription; Discontinued
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 68071-3093; 54288-140; 65862-538; 63415-0056; 68382-989; 17478-106; 70518-0932; 69097-282; 43063-457; 0143-9722; 61919-704; 80425-0076; 63187-384; 63323-355; 68083-415; 55111-279; 55150-156; 71335-0965; 67296-0897; 0904-6351; 70518-0968; 0781-5792; 67296-0972; 55154-5897; 42571-168; 51407-429; 50090-4572; 71335-0593; 63629-8070; 53002-3350; 68071-4512; 63187-514; 69097-289; 52343-120; 13668-083; 52343-121; 67296-1641; 55150-157; 0781-5791; 36000-295; 80425-0007; 68071-4926; 55111-281; 71205-234; 50090-1228; 65977-0039; 50090-2001; 67296-0975; 53002-2350; 55154-5898; 36000-294; 44567-436; 0143-9720; 44567-437; 63187-003; 68071-2074; 0143-9316; 68071-1860; 63187-833; 69097-287; 53002-2582; 53104-7550; 55111-280; 43063-637; 36000-048; 50383-286; 68071-4874; 68071-3166; 68180-241; 43063-459; 58118-1022; 68071-4726; 25021-132; 71335-0327; 71335-0133; 68071-4875; 67296-0977; 42708-122; 43063-638; 51407-430; 68180-242; 0527-1948; 0143-9721; 63187-925; 53069-0600; 68083-414; 71335-0391; 67296-1393; 50090-4797; 63187-004; 71335-0794; 68083-395; 50090-2498; 68071-3236; 71335-0434; 65841-692; 67296-1351; 71335-0380; 70934-094; 72578-098; 68071-4738; 43235-0007; 65841-691; 36000-296; 68071-3218; 63629-7681; 63187-438; 67296-0985; 31722-723; 65862-488; 65862-536; 54348-611; 50090-3214; 67296-1535; 72578-099; 0143-9317; 66721-200; 70518-2249; 61919-440; 43063-796; 53002-1350; 70934-050; 68788-6938; 0409-0528; 33342-023; 0781-5790; 67296-0744; 72578-100; 65841-693; 17478-107; 51407-428; 68083-416; 50090-4573; 49587-102; 68071-4900; 31722-722; 13668-084; 63629-4843; 61919-426; 65862-537; 70518-0453; 71205-002; 13668-082; 67296-1400; 68788-6816; 71335-0525; 80425-0009; 50090-4928; 70934-392; 67296-1546; 70771-1079; 52343-119; 45865-758; 36000-046; 44567-435; 55700-729; 0904-6353; 61919-987; 71335-1277; 31722-721; 68083-394; 68180-240; 67296-1325; 80425-0008; 72189-338; 36000-045; 67296-0998; 70518-2145; 71205-058; 72789-085; 80425-0077; 33342-022; 53002-1391; 0904-6352; 55525-0001; 36000-047; 71335-1208; 0143-9315; 33342-021
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.001--
Delirium19.13.02.0010.004940%
Delusion19.10.01.0010.000953%
Depressed level of consciousness17.02.04.0020.001040%
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Derealisation19.10.02.0010.000347%Not Available
Dermatitis23.03.04.0020.000520%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000867%Not Available
Dermatitis bullous23.03.01.0020.000693%
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000347%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000693%Not Available
Discomfort08.01.08.0030.001127%Not Available
Disorientation19.13.01.002; 17.02.05.0150.003293%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Disturbance in attention19.21.02.002; 17.03.03.0010.001473%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dizziness postural02.01.02.005; 24.06.02.008; 17.02.05.0040.000260%Not Available
Drug abuse19.07.02.010--Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.001820%Not Available
Drug hypersensitivity10.01.01.0010.067256%Not Available
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.0010.000433%
Dry mouth07.06.01.0020.001300%
Dry skin23.03.03.001--
Dysaesthesia17.02.06.0030.000433%
Dysarthria19.19.03.001; 17.02.08.0010.000780%
Dysgeusia17.02.07.003; 07.14.03.001--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 30 Pages